成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Inhibitors>Metabolism>PDE inhibitors>Cilomilast
Cilomilast
  • Cilomilast

Cilomilast NEW

Price $48 $89 $161
Package 5mg 10mg 25mg
Min. Order:
Supply Ability: 10g
Update Time: 2024-11-11

Product Details

Product Name: Cilomilast CAS No.: 153259-65-5
Purity: 99.43% Supply Ability: 10g
Release date: 2024/11/11

Product Introduction

Bioactivity

名稱Cilomilast
描述Cilomilast (SB-207499) is a potent PDE4 inhibitor with an IC50 of approximately 110 nM, demonstrating anti-inflammatory activity and minimal central nervous system effects. Phase 3.
細(xì)胞實(shí)驗(yàn)U937 cells (1-2 × 10 6) are incubated at 37 °C in a shaking water bath with Cilomilast for 1 min before the addition of 0.1 μM PGE2 (total volume of 200 μL). The incubation proceeds for an additional 4 min and is stopped by the addition of 0.1 mL of HClO4 (17.5%), neutralized with 0.15 ml of K2
體外活性Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. [2] In isolated human monocytes, Cilomilast and (R)-rolipram are equipotent at suppressing LPS-induced TNF-α formation with -log (IC50) of 7.0 and 7.2, respectively. Both Cilomilast and (R)-rolipram produces a modest prevention of fMLP-induced degranulation of human neutrophils. Cilomilast and (R)-rolipram are equipotent at suppressing neutrophil activation with -log (IC50) of 7.1 and 6.4, respectively. [2] Cilomilast significantly decreases the expression of TNF-α in the cornea and IL-1α, IL-1β, and TNF-α in the conjunctivaas compared to vehicle control. Cilomilast treatment markedly decreases the presence of CD11b+ antigen-presenting cells in the central and peripheral cornea, and leads to decreased conjunctival expression of cytokines IL-6, IL-23, and IL-17. Moreover, Cilomilast decreases the expression of IL-17 and IL-23 in the draining lymph nodes. [3] Cilomilast reduces TLR4 expression, IL-8 release and neutrophil chemotactic activity as well as it increased IP-10 release and lymphocyte chemotactic activity. [4]
體內(nèi)活性Cilomilast inhibits human TNFα production with oral ED50 of 4.9 mg/kg. In contrast to their equipotent activity against TNFα production, Cilomilast (ED50 = 2.3 mg/kg, p.o.) is 10-fold less potent than R-rolipram (ED50 = 0.23 mg/kg, p.o.) in reversing reserpine-induced hypothermia, a model of antidepressant activity. [1] In time course studies, Cilomilast (30 mg/kg, p.o.) suppresses TNFα production for at least 10 hour. The ability of Cilomilast to modulate interleukin-4 productionin vivo is assessed in a chronic oxazolone-induced contact sensitivity model in Balb/c mice. Topical administration of Cilomilast (1000 μg) inhibits intralesional concentrations of interleukin-4. [1] Orally administered cilomilast dose-dependently inhibits production of interleukin-4, TNF-α, and cysteinyl leukotrienes, as well as leukocyte infiltration in bronchoalveolar lavage fluid from the airways of ovalbumin-sensitized Brown Norway rats [5].
存儲(chǔ)條件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度Ethanol : 31 mg/mL (90.3 mM)
DMSO : 60 mg/mL (174.71 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
關(guān)鍵字asthma | immunomodulatory | obstructive | Inhibitor | Phosphodiesterase (PDE) | inhibit | SB207499 | Phosphodiesterase | SB 207499 | pulmonary | disease | PDE4 | anti-inflammatory | COPD | Cilomilast | chronic
相關(guān)產(chǎn)品Theophylline monohydrate | Roflumilast | Theobromine | Apremilast | Isoprenaline hydrochloride | Indomethacin | Icariin | Theophylline | Vardenafil hydrochloride | Doxofylline
相關(guān)庫(kù)經(jīng)典已知活性庫(kù) | 神經(jīng)退行性疾病化合物庫(kù) | 抗阿爾茨海默癥化合物庫(kù) | 藥物功能重定位化合物庫(kù) | 抑制劑庫(kù) | 抗心血管疾病化合物庫(kù) | 口服活性化合物庫(kù) | 抗衰老化合物庫(kù) | 臨床期小分子藥物庫(kù) | 已知活性化合物庫(kù)

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$15.00/1KG
Zhuozhou Wenxi import and Export Co., Ltd
2021-07-10
$1.00/1g
VIP5Y
Career Henan Chemical Co
2020-01-10
$0.00/5mg
VIP5Y
Shaanxi Dideu Medichem Co. Ltd
2019-12-30
$15.00/1KG
Zhuozhou Wenxi import and Export Co., Ltd
2021-07-09
  • Since: 2011-01-07
  • Address: 36?Washington?Street, Wellesley?Hills
INQUIRY